Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
نویسندگان
چکیده
منابع مشابه
Advanced alveolar soft part sarcoma responds to apatinib
Alveolar soft part sarcoma (ASPS) is a rare, hypervascular soft tissue sarcoma with a low chemotherapy response rate. Here, we report an ASPS case with multiple lung metastases on initial presentation. The primary tumor, a hypervascular soft tissue mass 4.1×3.2×2.0 cm, located in the right thigh, was resected prior to chemotherapy. The patient suffered disease progression after two cycles of ge...
متن کاملOff-label use of vaccines.
This article reviews the off-label recommendations and use of vaccines, and focuses on the differences between the labelled instructions on how to use the vaccine as approved by the regulatory authorities (or "label"1), and the recommendations for use issued by public health advisory bodies at national and international levels. Differences between public health recommendations and the product l...
متن کاملoff-label and off-nccn guidelines uses of antineoplastic drugs in china.
to evaluate off-label and off-nccn guidelines uses of antineoplastic drugs in a major chinese hospital.totally 1122 patients were selected from july to december 2011. then, the off-label and off-nccn guidelines uses of antineoplastic drugs were analyzed.in 798 of 1122 patients (71.12%), drugs were used for off-label. in 317 of 1122 patients (28.25%), the drugs were prescribed for off-label and ...
متن کاملOff-label use of misoprostol in gynaecology
Clinical use of drugs is approved for specified clinical indication, route of administration, dose and population group. Off-label prescribing of a registered medicine occurs outside of these parameters and may be justified by pharmacology and physiology, as well as sufficient evidence from published clinical trials and reviews. Misoprostol and mifepristone in combination have recently been reg...
متن کاملOff-label drug use in pediatric patients.
INTRODUCTION Until recently, it was considered unethical or impossible to perform clinical trials of new medicines in children. As a consequence, many medicines used for treating children are insufficiently documented with regard to dosing, efficacy, and safety. The off-label use of drugs has been extensive in treating the pediatric population. This article gives an overview of the extent and t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Cancer
سال: 2018
ISSN: 1471-2407
DOI: 10.1186/s12885-018-4303-z